Leveraging our know-how and R&D approach, we have implemented a product development model that consists of internal discovery, business development and translational research.
- Internal Discovery
- Business Development
- Translational Research
Deep understanding
into fundamental
disease biology and clinical practice
Integrated operation
that well-positions us to capture international business opportunities
Seasoned management team
Our portfolio now covers oncology, liver fibrosis and rare diseases.
Drug Candidate
Target Mechanism
Indications
Lead
Discovery
Proof of
Mechanism
CMC IND Enabling
Phase I
Phase II
Phase III
Cancer
Glossary & abbreviations
PROC: platinum-resistant ovarian cancer mCPRC: metastatic castration-resistant prostate cancer mHSPC: metastatic hormone-sensitive prostate cancer ER: estrogen receptor TNBC: triple negative breast cancer
As of June 30, 2023
AKT + Chemotherapy
PROC (second- to sixth-line treatment)
Global
AKT + CYP17A
mCRPC following SOC Treatment (second- to fourth-line treatment)
Global
AKT + PD-1+Chemotherapy
PD-1/PD-LI Resistant Solid Tumors
Global
AKT + PD-L1+chemotherapy
TNBC (second- to third-line treatment)
Global
AKT + ER
Locally Advanced or Metastatic HR+/HER2-Breast Cancer (second- to third-line treatment)
Global
CYP17A/CYP11B2
mHSPC (first-line treatment)
Global
ActRIIA
Cancer
Global
NK/T regulator
Cancer
Global
LILRB1-B2
bispecific
Cancer
Global
TIGIT-PVRIG
bispecific
Cancer
Global
NK/T regulator
Cancer
Global
FGFR2b mAb
Cancer
Global
PI3Kα mutant-
selective
Cancer
Global
PARP1-selective
Cancer
Global
USP1
Cancer
Global
aHSC depletion
Liver Fibrosis
Global
aHSC depletion
Liver Fibrosis
Global
Conditional TGFß blocker
Liver Fibrosis
Global
Glossary & abbreviations
PROC: platinum-resistant ovarian cancer mCRPC: metastatic castration-resistant prostate cancer mBC: metastatic breast cancer TNBC: triple negative breast cancer HHT: hereditary hemorrhagic telangiectasia ET: endocrine therapy AI: aromatase inhibitors
As of May 31, 2022
Conditions | Interventions | Study Title | Status |
---|---|---|---|
Solid Tumor TNBC Triple-Negative Breast Cancer |
Combination Product |
PhI to Solid Tumors and PhII to Locally Advanced or mTNBC |
Recruiting |
Platinum-resistant Ovarian Cancer |
Drug: Paclitaxel Drug: Afuresertib |
Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian |
Recruiting |
Solid Tumor NSCLC Cervical Cancer Endometrial Cancer Esophageal CancerGastric and Gastroesophageal Junction Adenocarcinoma |
Drug: Afuresertib Drug:Nab paclitaxel Drug: Docetaxel Drug: Sintilimab |
Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1 |
Recruiting |
Metastatic Castration-resistant Prostate Cancer |
Drug: Phase I and Phase II: LAE001/prednisone + afuresertib |
Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC |
Active, not recruiting |
Breast Cancer |
Drug: Afuresertib |
Study Evaluating Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients w/ Locally Advanced or Metastatic HR+/HER2- Breast Cancer |
Recruiting |
In the 1990s, due to his passion for biotechnology, Dr. Xiangju Gu left his homeland to study and work overseas. Later, in order to realize hist dream of developing new drugs in China, he followed his heart and devoted to the wave of pharma innovation in Zhangjiang.
Follow us on Linkedin